Jun 09, 2021 / 02:00AM GMT
Presentation
Jun 09, 2021 / 02:00AM GMT
=====================
Corporate Participants
=====================
* Haruo Naito
Eisai Co., Ltd. - CEO, Representative Corporate Officer & Director
* Ivan Cheung
Eisai Co., Ltd. - Senior VP & President of Neurology Business Group
* Shuhei Shimizu
* Teiji Kimura
Eisai Co., Ltd. - VP & Chief Discovery Officer of Neurology Business Group
=====================
Conference Call Participants
=====================
* Fumiyoshi Sakai
Crédit Suisse AG, Research Division - Research Analyst
* Hidemaru Yamaguchi
Citigroup Inc., Research Division - Research Analyst
* Motoya Kohtani
Nomura Securities Co. Ltd., Research Division - Senior Analyst
=====================
Unidentified Company Representative
[Interpreted] Now it is time to start meeting, Eisai Company Limited's conference call. Today, we'd like to talk about the accelerated approval of aducanumab given by U.S. FDA.
Now without further ado, I'd
Eisai Co Ltd FDA Grants Accelerated Approval for ADUHELM Presentation Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot